Masahiro Tsuboi

Completely resected stage IIIA non-small cell lung cancer: the significance of primary tumor location and N2 station.

M. Tsuboi, R. Tsuchiya, T. Mitsudomi, 2001, The Journal of thoracic and cardiovascular surgery.

Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel.

M. Tsuboi, K. Eguchi, N. Saijo, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer in Japanese patients from CheckMate 816.

S. Oizumi, Y. Ohde, K. Takamochi, 2023, Cancer science.

Feasibility trial for adjuvant chemotherapy with docetaxel plus cisplatin followed by single agent long-term administration of S-1 chemotherapy in patients with completely resected non-small cell lung cancer: Thoracic Oncology Research Group Study 0809

M. Tsuboi, Y. Hosomi, N. Ikeda, 2013, British Journal of Cancer.

NOTCH1 and CREBBP co‐mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR‐mutated NSCLC: translational research of phase III IMPACT study

Y. Ohde, H. Akamatsu, H. Tada, 2023, Molecular oncology.